alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › simoa

simoa

4 studies tagged simoa, dated 2019-12-12 to 2024-08-22. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA 2024-08-22
  2. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms 2024-04-23
  3. CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 2023-09-04

Studies

4 studies carry this tag.

Date range

2019 to 2024

Top journals

  • Clinical chemistry and laboratory medicine 1
  • International journal of molecular sciences 1
  • Neurobiology of aging 1
  • Neurology and therapy 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Plasma p-tau181 and amyloid markers in Alzheimer's disease: A comparison between Lumipulse and SIMOA

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurobiology of aging 2024-08-22 Biomarkers

    One-hundred-thirthy-three participants, namely 55 A+T+N+ AD, 28 Neurodegenerative disorders (NDD) and 50 controls were enrolled for the study.

  2. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. International journal of molecular sciences 2024-04-23 Biomarkers

    We compared the clinical and analytical performance of Alzheimer's disease (AD) plasma biomarkers measured using the single-molecule array (Simoa) and Lumipulse platforms.

  3. CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Clinical chemistry and laboratory medicine 2023-09-04 Biomarkers

    Differences observed in technical and diagnostic performance of the two assays may depend on matrix-specific amyloid processing, suggesting that further studies should be carried to standardize amyloid ratio measurement in plasma.

  4. An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurology and therapy 2019-12-12 Biomarkers

    The development of blood-based biomarkers of Alzheimer's disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential.

All topic tags with their study counts